Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

ClinicalTrials.gov ID: NCT00102726

Public ClinicalTrials.gov record NCT00102726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy

Study identification

NCT ID
NCT00102726
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
183 participants

Conditions and interventions

Interventions

  • SB497115 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2005
Primary completion
Jan 31, 2007
Completion
Jan 31, 2007
Last update posted
Mar 22, 2017

2005 – 2007

United States locations

U.S. sites
27
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85715
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Greenbrae California 94904-2007
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Newark Delaware 19718
GSK Investigational Site Boca Raton Florida 33428
GSK Investigational Site Hollywood Florida 33021
GSK Investigational Site Tamarac Florida 33321
GSK Investigational Site Savannah Georgia 31405
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Baltimore Maryland 21237-3998
GSK Investigational Site Minneapolis Minnesota 55455
GSK Investigational Site Hattiesburg Mississippi 39401
GSK Investigational Site Tupelo Mississippi 38801
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site Babylon New York 11702
GSK Investigational Site New York New York 10032
GSK Investigational Site Durham North Carolina 27707
GSK Investigational Site Akron Ohio 44304
GSK Investigational Site Mayfield Heights Ohio 44124
GSK Investigational Site Toledo Ohio 43614-5809
GSK Investigational Site Bryan Texas 77802
GSK Investigational Site Ogden Utah 84403
GSK Investigational Site Salem Virginia 24153

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00102726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00102726 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →